Heart failure is a serious condition that affects millions of people worldwide. It occurs when the heart is unable to pump blood effectively, which can lead to a variety of symptoms, including shortness of breath, fatigue, and swelling in the legs. Heart failure can be a progressive condition, and it can eventually lead to death.
Sacubitril/valsartan is a fixed-dose combination medication for use in heart failure. It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan. The combination is sometimes described as an "angiotensin receptor-neprilysin inhibitor".
Sacubitril/valsartan works by increasing the levels of natriuretic peptides, which are hormones that help to relax the heart and improve its pumping function. The drug also blocks the effects of angiotensin II, a hormone that can cause the heart to become stiff and less efficient.
Sacubitril/valsartan has been shown to significantly improve survival in patients with heart failure. In clinical trials, sacubitril/valsartan was shown to reduce the risk of death by 20% compared to standard treatments for heart failure.
Sacubitril/valsartan is generally well-tolerated, but it can cause some side effects, including:
Sacubitril/valsartan should not be taken by people who are allergic to sacubitril or valsartan. It should also not be taken by people who are taking other drugs that contain neprilysin inhibitors.
In the Philippines, Sacubitril/valsartan is available in the following configurations:
50 mg tablet: P88.00 per tablet
100 mg tablet: P88.00 per tablet
200 mg tablet: P88.00 per tablet
Sacubitril/valsartan is available by prescription only. In the Philippines, it is exclusively available in TGP (The Generics Pharmacy).
Sacubitril/valsartan is a breakthrough treatment for heart failure. It is the first drug to significantly improve survival in patients with this condition. If you are living with heart failure, talk to your doctor about whether sacubitril/valsartan may be right for you.
Sources:
http://en.wikipedia.org/wiki/Sacubitril/valsartan
https://www.ncbi.nlm.nih.gov/books/NBK507904/